Bicycle Therapeutics (FRA:50BA) LT-Debt-to-Total-Asset: 0.02 (As of Mar. 2026)

What is Bicycle Therapeutics LT-Debt-to-Total-Asset?

Bicycle Therapeutics FRA:50BA -0.55% 56 LT-Debt-to-Total-Asset is 0.02 as of Mar. 2026. GuruFocus rates FRA:50BA with a GF Score™ of 56/100 and a GF Value™ of €12.18 (Possible Value Trap). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Bicycle Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.02.

Bicycle Therapeutics's long-term debt to total assets ratio increased from Mar. 2025 (0.00) to Mar. 2026 (0.02). It may suggest that Bicycle Therapeutics is progressively becoming more dependent on debt to grow their business.

Bicycle Therapeutics (FRA:50BA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Bicycle Therapeutics LT-Debt-to-Total-Asset Related Terms

Bicycle Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Bicycle Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicycle Therapeutics LT-Debt-to-Total-Asset Chart

Bicycle Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.09

0.10

0.07

0.00

0.02

Bicycle Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.00	0.00	0.00	0.02	0.02

56GF Score

Bicycle Therapeutics PLC FRA:50BA

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Bicycle Therapeutics LT-Debt-to-Total-Asset Calculation

Bicycle Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	12.038	/	612.828
	=	0.02

Bicycle Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	12.001	/	564.323
	=	0.02

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.02 mean?

Bicycle Therapeutics (FRA:50BA) has a LT-Debt-to-Total-Asset of 0.02 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Bicycle Therapeutics and its competitors.

Is Bicycle Therapeutics' LT-Debt-to-Total-Asset too high?

Bicycle Therapeutics' current LT-Debt-to-Total-Asset is 0.02. Overall, Bicycle Therapeutics has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Bicycle Therapeutics' LT-Debt-to-Total-Asset compare to IFRX and ELDN?

Bicycle Therapeutics' LT-Debt-to-Total-Asset of 0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Bicycle Therapeutics and its competitors. Bicycle Therapeutics's current LT-Debt-to-Total-Asset is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Bicycle Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Bicycle Therapeutics (FRA:50BA) is currently considered Possible Value Trap. The stock's GF Value™ is €12.18, compared to a current price of €3.60 — trading 70.4% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.02. Bicycle Therapeutics' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Bicycle Therapeutics (FRA:50BA), the current LT-Debt-to-Total-Asset is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bicycle Therapeutics (FRA:50BA) Overvalued in 2026?

Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued. The current stock price of €3.60 is trading 70.4% below its estimated GF Value™ of €12.18. GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:50BA:

LT-Debt-to-Total-Asset: 0.02
GF Value™: €12.18 vs. price of €3.60 (70.4% below fair value)
GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the FRA:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bicycle Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies IFRX ELDN ZNTL GLSI SABS SRZN CNXU RNAC LYEL NMRA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges BCYC:USA 50BA:Germany

Address Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS

Website https://www.bicycletherapeutics.com

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.

56GF Score

Get the complete analysis for FRA:50BA

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.60

Price

€12.18

GF Value

View FRA:50BA Analysis

See LT-Debt-to-Total-Asset data for all stocks →